The Growth Hormone Axis: GHRH, Ghrelin, and Somatostatin

The Three Players

Growth hormone regulation involves three hypothalamic signals that converge on the pituitary gland. Understanding their interplay is the key to understanding everything about GH secretagogues, GH replacement, and age-related GH decline.

GHRH (Growth Hormone Releasing Hormone) comes from the arcuate nucleus of the hypothalamus. It's the primary stimulatory signal — it tells the pituitary somatotroph cells to synthesize and release GH.

Somatostatin (also called SRIF or GHIH) comes from the periventricular nucleus. It's the primary inhibitory signal — it tells the somatotrophs to stop releasing GH. It doesn't prevent GH synthesis, just secretion.

Ghrelin comes primarily from the stomach (with some hypothalamic production). It amplifies GH release through its own receptor (GHS-R) and also suppresses somatostatin release, effectively both pressing the gas and releasing the brake.

The interplay of these three signals produces the characteristic pulsatile GH secretion pattern: bursts of GH release separated by troughs of near-zero circulating GH.

GHRH: The Accelerator

GHRH is a 44-amino-acid peptide, though only the first 29 amino acids are needed for full biological activity (which is why sermorelin, the first 29 AAs, works as a GHRH analog). It binds to the GHRH receptor on pituitary somatotrophs and activates a cAMP signaling cascade that both increases GH gene transcription and triggers release of stored GH granules.

GHRH is released in pulses, roughly every 2-3 hours. The largest GHRH pulse occurs about an hour after sleep onset, which is why the biggest GH pulse of the day happens during early sleep.

GHRH can't produce a GH pulse on its own if somatostatin tone is high. The timing of GH pulses depends on windows when somatostatin drops low enough for GHRH to have its effect. This is why the two signals together create pulses rather than a continuous output.

Somatostatin: The Brake

Somatostatin is a 14-amino-acid peptide (there's also a 28-AA form) that acts as a universal inhibitor — it suppresses not just GH but also TSH, insulin, glucagon, and various GI hormones. It's one of the most widespread inhibitory peptides in the body.

For GH regulation specifically, somatostatin does two things: it blocks GH release from the pituitary, and it blocks GHRH release from the hypothalamus. It's a double brake.

Somatostatin tone isn't constant. It oscillates, and when it drops, GH pulses can occur. This oscillation is what creates the pulsatile pattern. Between pulses, somatostatin is high and GH is suppressed to near-zero. During pulses, somatostatin drops, GHRH activates, and GH surges.

This is why ghrelin mimetics like ipamorelin are valuable: by suppressing somatostatin, they create wider windows for GH release. Combined with GHRH analog stimulation, you get amplified pulses.

Ghrelin: The Wild Card

Ghrelin was only discovered in 1999, making it the newest addition to our understanding of the GH axis. It was found in the stomach, which was surprising — nobody expected a gut hormone to be a major GH regulator.

Ghrelin acts through the GHS-R (Growth Hormone Secretagogue Receptor), which was actually identified before ghrelin itself. Researchers found the receptor in 1996 while studying synthetic GH-releasing peptides (the GHRP series), and then spent three years searching for its natural ligand.

Ghrelin's GH-releasing effect is synergistic with GHRH. When both are present, the GH pulse is much larger than the sum of their individual effects. This synergy is the pharmacological basis for combining a GHRH analog (CJC-1295) with a ghrelin mimetic (ipamorelin).

Ghrelin also has functions beyond GH: it stimulates appetite (the "hunger hormone"), promotes fat storage, and influences sleep architecture. These effects explain why some GH secretagogues (particularly GHRP-6) cause significant hunger — they're activating the same receptor that natural ghrelin uses to signal feeding behavior.

The IGF-1 Feedback Loop

GH doesn't work alone. Many of its downstream effects are mediated by IGF-1 (Insulin-like Growth Factor 1), produced primarily by the liver in response to GH stimulation. IGF-1 is the workhorse that drives growth, tissue repair, and many of the body composition effects attributed to GH.

IGF-1 also feeds back to suppress GH. It acts at both the hypothalamus (increasing somatostatin release and decreasing GHRH) and the pituitary (directly inhibiting somatotroph responsiveness). This creates a classic negative feedback loop: GH stimulates IGF-1, IGF-1 suppresses GH.

This feedback is why exogenous GH (somatropin) suppresses natural GH production. The high IGF-1 levels generated by injected GH activate the feedback loop, shutting down endogenous GH secretion. When exogenous GH is discontinued, it takes time for the axis to recover.

GH secretagogues, by contrast, work within the feedback loop. They amplify natural GH pulses, which raises IGF-1, which provides feedback. The system self-limits. This is a fundamental pharmacological advantage of secretagogues over replacement therapy.

Why Pulsatility Matters

GH isn't just about how much is released. The pattern of release carries biological information. Continuous GH elevation and pulsatile GH release produce different downstream effects, even at the same total daily GH output.

In rodent studies, pulsatile GH drives longitudinal bone growth and lean mass gain, while continuous GH drives liver IGF-1 production and fat distribution. The male growth pattern (tall, lean) is associated with large, infrequent GH pulses. The female pattern is more continuous and lower-amplitude.

This has practical implications for GH therapy. Exogenous GH injected once daily produces a single pharmacological peak followed by a gradual decline — not quite the same as natural pulsatility. CJC-1295 with DAC produces sustained elevation. CJC-1295 without DAC + ipamorelin produces discrete pulses that more closely mimic physiology.

Which pattern is "best" depends on the research goal. For body composition, the evidence supports pulsatile release. For IGF-1 generation (and its downstream healing effects), continuous elevation may be adequate.

The Aging GH Axis

The decline in GH with aging (somatopause) is one of the most consistent endocrine changes in human biology. By age 60, 24-hour GH secretion is roughly 20% of what it was at age 20.

What causes this? The research points to multiple changes:

• Increased somatostatin tone — the brake gets stronger with age, suppressing GH pulses more effectively
• Decreased GHRH amplitude — the hypothalamic "go" signal weakens
• Reduced ghrelin sensitivity — the amplification pathway becomes less effective
• Changes in body composition — increased visceral fat produces more free fatty acids and insulin, both of which suppress GH

GH secretagogues address several of these age-related changes. GHRH analogs compensate for reduced GHRH amplitude. Ghrelin mimetics reduce somatostatin tone and restore ghrelin responsiveness. This is why secretagogues are particularly interesting in the context of aging research — they're not replacing a hormone but restoring a signaling pathway.